This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SORBS3 · Western blot design guide
SORBS3 Western Blot Planning Guide
Plan a SORBS3 Western blot around the catalog-observed 75.3 kDa band, image-backed A05794 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
SORBS3 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 75.3 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Heart muscle | |
| Negative control | Bone marrow |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 75.3 kDa |
| ⓘ | Localization | Cell junction / Cytoplasm, cytoskeleton |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated SORBS3 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Heart muscle |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A05794 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected SORBS3 Western Blot Band Size?
Use the product-observed 75.3 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 75.3 kDa | Matches the authoritative product WB observation. |
| 75.3 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected SORBS3 appearancePlan around 75.3 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 75.3 kDa; use this as the primary experimental expectation. |
| Calculated mass | 75.3 kDa from UniProt O60504; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A05794. |
| Situation | Likely cause | Next action |
|---|---|---|
| 75.3 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing SORBS3 band
A05794 · SORBS3
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for SORBS3 Western blot
🧪Use Heart muscle as the first positive-control candidate and Bone marrow as the HPA Not detected negative candidate.
Positive control: Heart muscle (High)
Negative control: Bone marrow (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for SORBS3
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Heart muscle | Reported tissue cells | High | Protein (HPA) | HPA → |
| Skeletal muscle | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced SORBS3 Western Blot Tips
Deeper troubleshooting and optimisation questions for SORBS3, answered from its protein features.
Which band should guide the blot?
Use 75.3 kDa, the observation attached to the authoritative A05794 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 75.3 kDa expectation.
Which positive control should I start with?
Start with Heart muscle, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bone marrow as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for SORBS3 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A05794 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
SORBS3 Western Blot Reagents
Human/Mouse/Rat-reactive SORBS3 Western blot reagents with authoritative product imagery.
Real WB data
Anti-Vinexin/SORBS3 Antibody Picoband®
Cat # A05794
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt O60504
- Human Protein Atlas — SORBS3
- A05794 product record
- PMC11978191 — SORBS3-β suppresses lymph node metastasis in cervical cancer by promoting the ubiquitination of β-catenin (Journal of translational medicine, 2025)
- PMC10084591 — Elevated ZNF704 expression is associated with poor prognosis of uveal melanoma and promotes cancer cell growth by regulating AKT/mTOR signaling (Biomarker research, 2023)
- PMC5098049 — Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma (Hepatology (Baltimore, Md.), 2016)